Duloxetine Delayed-Release Capsules USP, 60 mg, 1000-count bottles, Rx Only, Manufactured by Towa...
FDA Drug Recall #D-0387-2025 - Class II, April 14, 2025
Recall Summary
| Recall Number | D-0387-2025 |
| Classification | Class II - Moderate risk |
| Date Initiated | April 14, 2025 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Breckenridge Pharmaceutical, Inc |
| Location | Berlin, CT |
| Product Type | Drugs |
| Quantity | 16,473 bottles |
Product Description
Duloxetine Delayed-Release Capsules USP, 60 mg, 1000-count bottles, Rx Only, Manufactured by Towa Pharmaceutical Europe, S.L., Distributed by Breckenridge Pharmaceutical, Inc. Berkeley Heights, NJ 07922, NDC# 51991-748-10
Reason for Recall
CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
Distribution Pattern
US Nationwide.
Lot / Code Information
Lot # 240987C, exp. date 04/2027 241014C, exp. date 04/2027
Other Recalls from Breckenridge Pharmaceutical, Inc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0388-2025 | Class II | Duloxetine Delayed-Release Capsules USP, 30 mg,... | Apr 14, 2025 |
| D-0161-2025 | Class II | Duloxetine Delayed-Release Capsules, USP, 30mg,... | Dec 6, 2024 |
| D-0162-2025 | Class II | Duloxetine Delayed-Release Capsules, USP, 60 mg... | Dec 6, 2024 |
| D-0009-2025 | Class II | Duloxetine Delayed-Release Capsules, USP, 20mg,... | Oct 10, 2024 |
| D-0562-2024 | Class II | Duloxetine Delayed-Release Capsules, USP, 60mg,... | May 17, 2024 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice, the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful, in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications, even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications, use a drug take-back program.